Received FDA Accelerated Approval For VOYXACT (Sibeprenlimab-Szsi) For The Reduction Of Proteinuria In Adults With Primary Immunoglobulin A Nephropathy (IgAN) At Risk For Disease Progression
25/11/2025 23:56
Nov 26 (Reuters) - Otsuka Holdings Co Ltd 4578.T: OTSUKA HOLDINGS CO LTD - OTSUKA RECEIVES FDA ACCELERATED APPROVAL FOR VOYXACT (SIBEPRENLIMAB-SZSI) FOR THE REDUCTION OF PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK FOR DISEASE PROGRESSION Source text: ID:nTSwy7c0f4 Further company coverage: 4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug